Compared with baseline, significant reductions in noninflammatory, inflammatory, and total lesions were seen in the first 4 weeks of treatment with CL-BP 3.75%.

Study results suggest that vitiligo is associated with an increase in primary hospitalizations for several mental health conditions.

Generally, women with AD decreased dermatologic therapy during pregnancy.

Data show an increased prevalence of psoriasis in patients with gout compared with patients without gout.

Data show that filgotinib is effective for the treatment of active psoriatic arthritis.

Alexithymia reversal was higher in patients who achieved control of their psoriasis, and reversal was associated with significant improvements in quality of life, anxiety, and depression.

The primary study outcome was the proportion of ulcers that healed within 20 weeks evaluated in the intention-to-treat population.

The approval was supported by data from 2 prospective, multicenter, randomized, double-blind clinical trials.

Higher incidence rates of subsequent BP have been reported in patients with brain and nervous system tumors than in those with other forms of cancer.

Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.